news archive

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

02.23.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02.17.2023

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

02.13.2023

BridgeBio Pharma to Participate in February and March Investor Events

02.08.2023

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

01.04.2023

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

12.22.2022

BridgeBio Pharma to Participate in November Investor Events

11.09.2022

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

11.03.2022

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

10.17.2022

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

10.14.2022

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

10.13.2022

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)

10.11.2022

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

10.07.2022

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

09.20.2022

BridgeBio Pharma to Participate in September Investor Events

09.06.2022

BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

08.18.2022

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

08.10.2022

BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update 

08.04.2022

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

07.26.2022

BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

07.25.2022

news archive

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BridgeBio disavows any obligation to update the information contained in such press releases after the date of their issuance.

back to news

icon icon